The company is substantially improved its course of a novel solution for ATTR-CM, utilizing the compound. Early patient results suggests significant improvements for individuals affected by this debilitating disease. https://biotech733707.targetblogs.com/42436932/bridgebio-progresses-attr-cm-therapy-using-the-therapy